<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962388</url>
  </required_header>
  <id_info>
    <org_study_id>RUXBETA trial</org_study_id>
    <nct_id>NCT02962388</nct_id>
  </id_info>
  <brief_title>The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line</brief_title>
  <official_title>A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective national multicenter randomized open label phase IIb RUXBETA trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open label, multicenter phase IIb study to evaluate the efficacy and safety of&#xD;
      Ruxolitinib versus best available therapy in patients with high risk essential&#xD;
      thrombocythemia, who are resistant or intolerant to hydroxyurea.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    not enough recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">January 3, 2017</start_date>
  <completion_date type="Actual">June 28, 2021</completion_date>
  <primary_completion_date type="Actual">June 28, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free patients</measure>
    <time_frame>month 12</time_frame>
    <description>Failure is defined by the occurrence of either intolerance and/or resistance to the second line therapy according to the protocol criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete hematologic response</measure>
    <time_frame>48 months</time_frame>
    <description>Number of Participants With normal Laboratory Values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE/SAE</measure>
    <time_frame>48 months</time_frame>
    <description>Rates, types and grades of AE/SAE related to the therapy, according to the NCI-CTCAE v4.0 classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median dose</measure>
    <time_frame>48 months</time_frame>
    <description>Median dose of the treatment received</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombotic and hemorrhagic events</measure>
    <time_frame>48 months</time_frame>
    <description>Cumulative incidence of thrombotic and hemorrhagic events incidence of progression into PV, secondary MF and MDS/acute leukemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>48 months</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Essential Thrombocythemia</condition>
  <arm_group>
    <arm_group_label>Reference therapy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational therapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib JAKAVI® Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing paradigm.&#xD;
Maximum dose 25 mg BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anagrelide</intervention_name>
    <description>Anagrelide in the study, according to the investigator decision fom day 1 to 48 months</description>
    <arm_group_label>Reference therapy arm</arm_group_label>
    <other_name>ARM A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib (JAKAVI®)</intervention_name>
    <description>Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months</description>
    <arm_group_label>Investigational therapy arm</arm_group_label>
    <other_name>ARM B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFNα/ PegIFNα</intervention_name>
    <description>IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months</description>
    <arm_group_label>Reference therapy arm</arm_group_label>
    <other_name>ARM A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Target Population&#xD;
&#xD;
          -  Men and women, age more than or equal18 years and less than 75 years.&#xD;
&#xD;
          -  Confirmed diagnosis of Essential Thrombocythemia for at least 6 months, according to&#xD;
             the 2008 WHO criteria, with a high-risk status.&#xD;
&#xD;
          -  Patients must have a treatment history for ET that meet the definition of resistance&#xD;
             or intolerance to hydroxyurea therapy according to the ELN criteria as follow:&#xD;
&#xD;
               -  Platelets more than 600.0109/L after 3 months (12 weeks) of treatment at a dose&#xD;
                  over 2g/day.&#xD;
&#xD;
               -  Platelets more than 400.0 109/L and WBC less than 2.5109/L, whatever the dose of&#xD;
                  HU.&#xD;
&#xD;
               -  Platelets more than 400.0 109/L and Hb less than 10g/dl whatever the dose of HU.&#xD;
&#xD;
               -  Leg ulcers or other unacceptable muco-cutaneous toxicity.&#xD;
&#xD;
               -  HU-related fever.&#xD;
&#xD;
          -  ECOG Performance Status (ECOG PS) less than or equal 2 at screening and at baseline.&#xD;
&#xD;
        Adequate Organ Function:&#xD;
&#xD;
          -  Direct bilirubin less than 2.0 times the institutional Upper Limit of Normal (ULN).&#xD;
&#xD;
          -  Hepatic enzymes (AST, ALT) less than or equal 2.5 times the institutional ULN.&#xD;
&#xD;
          -  Adequate renal function at screening as demonstrated by MDRD-eGFR more than 30&#xD;
             mL/min/1.73m2.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must be using an adequate method of&#xD;
             contraception to avoid pregnancy during and after the study.&#xD;
&#xD;
               -  A male subject of fathering potential must use an adequate method of&#xD;
                  contraception to avoid conception during and after the study to minimize the risk&#xD;
                  of pregnancy.&#xD;
&#xD;
               -  For females and males, these restrictions apply for 24 hours after the last dose&#xD;
                  of study drug.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum (beta-human chorionic&#xD;
             gonadotropin hCG pregnancy test at Screening.&#xD;
&#xD;
          -  Signed Written Informed Consent.&#xD;
&#xD;
          -  Health insurance coverage.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with thrombocytosis related to another MPN than ET&#xD;
&#xD;
          -  Patients previously treated with a JAK2 inhibitor, Anagrelide or Interferon-alpha and&#xD;
             prior history of therapy other than Hydroxyurea&#xD;
&#xD;
          -  Contraindication to Ruxolitinib, Anagrelide or Interferon-alpha (if no eligible for&#xD;
             anagrelide), hypersensitivity to an excipient&#xD;
&#xD;
        Medical history and concurrent diseases:&#xD;
&#xD;
          -  Clinically significant cardiac disease (NYHA Class III or IV).&#xD;
&#xD;
          -  Chronic hepatocellular disease.&#xD;
&#xD;
          -  Subjects with impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of Ruxolitinib&#xD;
&#xD;
          -  Subjects with clinically significant bacterial, fungal, parasitic or viral infection&#xD;
             which requires therapy:&#xD;
&#xD;
               -  Subjects with acute bacterial infections requiring antibiotic use should delay&#xD;
                  screening/enrolment until the course of antibiotic therapy has been completed.&#xD;
&#xD;
               -  Subjects with active hepatitis A, B or C or with HIV positivity at screening.&#xD;
&#xD;
               -  Subjects with diagnosed primary immunodeficiency syndromes such as X-Linked a&#xD;
                  gammaglobulinemia and common variable immune deficiency.&#xD;
&#xD;
               -  Subject with medical history of tuberculosis&#xD;
&#xD;
          -  History of progressive multifocal leucoencephalopathy (PML).&#xD;
&#xD;
          -  Other malignant disease during the last 5 years prior to the inclusion except treated&#xD;
             cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell&#xD;
             carcinoma of the skin, with no evidence for recurrence in the past 3 years.&#xD;
&#xD;
          -  History of significant bleeding disorder not related to the ET.&#xD;
&#xD;
               -  Diagnosed congenital bleeding disorders,&#xD;
&#xD;
               -  Diagnosed acquired bleeding disorder within one year (e.g. acquired anti-factor&#xD;
                  VIII antibodies),&#xD;
&#xD;
               -  Ongoing or recent (3 months) significant gastrointestinal bleeding.&#xD;
&#xD;
          -  Subjects with an uncontrolled undercurrent illness or any concurrent condition that,&#xD;
             in the investigator's opinion, would jeopardize the safety of the subject or&#xD;
             compliance with the protocol.&#xD;
&#xD;
          -  Subjects being treated concurrently with a potent systemic inhibitor of CYP3A4 at the&#xD;
             time of screening.&#xD;
&#xD;
          -  Subjects being treated concurrently with any prohibited medications.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding are not eligible for this study.&#xD;
&#xD;
          -  Inability to freely provide consent through judiciary or administrative condition.&#xD;
&#xD;
          -  Ongoing participation to another clinical investigational study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane GIRAUDIER, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>France Intergroupe Syndromes Myéloprolifératifs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LYDIA ROY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>France Intergroupe Syndromes Myéloprolifératifs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FILO</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO site</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anagrelide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>e crf</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

